These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28077493)

  • 1. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Button J; Al-Louzi O; Lang A; Bhargava P; Newsome SD; Frohman T; Balcer LJ; Frohman EM; Prince J; Calabresi PA; Saidha S
    Neurology; 2017 Feb; 88(6):525-532. PubMed ID: 28077493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Lambe J; Risher H; Filippatou AG; Murphy OC; Sotirchos ES; Ehrhardt H; Ogbuokiri E; Pellegrini N; Toliver B; Luciano NJ; Davis S; Fioravante N; Kwakyi O; Prince JL; Calabresi PA; Fitzgerald KC; Saidha S
    Neurology; 2021 May; 96(20):e2525-e2533. PubMed ID: 33827962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
    Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
    J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis.
    Behbehani R; Adnan H; Al-Hassan AA; Al-Salahat A; Alroughani R
    Mult Scler Relat Disord; 2018 Apr; 21():56-62. PubMed ID: 29459346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    Behbehani R; Abu Al-Hassan A; Al-Salahat A; Sriraman D; Oakley JD; Alroughani R
    PLoS One; 2017; 12(2):e0172120. PubMed ID: 28192539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy.
    Sotirchos ES; Gonzalez Caldito N; Filippatou A; Fitzgerald KC; Murphy OC; Lambe J; Nguyen J; Button J; Ogbuokiri E; Crainiceanu CM; Prince JL; Calabresi PA; Saidha S;
    Ann Neurol; 2020 Jun; 87(6):885-896. PubMed ID: 32285484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.
    Saidha S; Al-Louzi O; Ratchford JN; Bhargava P; Oh J; Newsome SD; Prince JL; Pham D; Roy S; van Zijl P; Balcer LJ; Frohman EM; Reich DS; Crainiceanu C; Calabresi PA
    Ann Neurol; 2015 Nov; 78(5):801-13. PubMed ID: 26190464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS.
    You Y; Barnett MH; Yiannikas C; Parratt JDE; Matthews JG; Graham SL; Klistorner A
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33597189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis.
    Gernert JA; Böhm L; Starck M; Buchka S; Kümpfel T; Kleiter I; Havla J
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
    Zivadinov R; Tavazzi E; Hagemeier J; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B
    CNS Drugs; 2018 Aug; 32(8):763-770. PubMed ID: 29767815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of disease modifying therapy and retinal atrophy in relapsing-remitting multiple sclerosis.
    Kabanovski A; Zaslavsky K; Rotstein D; Margolin E
    J Neurol Sci; 2023 Mar; 446():120552. PubMed ID: 36774748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
    Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
    Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    Huhn K; Lämmer R; Zimmermann H; Lämmer A; Waschbisch A; Utz K; Gieß RM; Paul F; Linker RA; Lee DH
    J Neurol Sci; 2016 Nov; 370():1-6. PubMed ID: 27772735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis.
    Glasner P; Sabisz A; Chylińska M; Komendziński J; Wyszomirski A; Karaszewski B
    Restor Neurol Neurosci; 2022; 40(1):35-42. PubMed ID: 35180139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.
    Moccia M; Santoni L; Vaccari I; Affinito G; Caliendo D; Rubba F; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
    Bsteh G; Hegen H; Krajnc N; Föttinger F; Altmann P; Auer M; Berek K; Kornek B; Leutmezer F; Macher S; Monschein T; Ponleitner M; Rommer P; Schmied C; Zebenholzer K; Zulehner G; Zrzavy T; Deisenhammer F; Di Pauli F; Pemp B; Berger T
    Mult Scler; 2024 Aug; 30(9):1128-1138. PubMed ID: 39109593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Sotirchos ES; Vasileiou ES; Filippatou AG; Fitzgerald KC; Smith MD; Lord HN; Kalaitzidis G; Lambe J; Duval A; Prince JL; Mowry EM; Saidha S; Calabresi PA
    Neurology; 2022 Aug; 99(7):e688-e697. PubMed ID: 35618438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyper-reflective foci changes in RRMS under natalizumab therapy.
    Puthenparampil M; Basili E; Ponzano M; Mauceri VA; Miscioscia A; Pilotto E; Perini P; Rinaldi F; Bovis F; Gallo P
    Front Immunol; 2024; 15():1421755. PubMed ID: 39076978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.